A hypothetical model for receptor binding of leukotriene D4 (LTD4) was deduced from conformational analysis of LTD4 and from the structure-activity relationships (SAR) of known LTD4 receptor antagonists. A new structural series of LTD4 receptor antagonists exemplified by 5-[4-(4-phenylbutoxy)phenyl]-2-[4-(tetrazol-5-yl)butyl]-2H-t etrazole was designed in which a phenyltetrazole moiety was incorporated as a receptor binding equivalent of the triene unit of LTD4. A number of these phenyltetrazoles were prepared and found to possess LTD4 receptor antagonist activity. The structure-activity relationship (SAR) of this series is described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm00085a004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cysteine Leukotriene Receptor Antagonist-Montelukast-Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice.
Cardiovasc Ther
January 2025
Institute of Cardiovascular Science, Translational Medicine Institute, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China.
Cysteinyl leukotrienes (LTs) and their receptors are involved in the pathogenesis of abdominal aortic aneurysms (AAAs). However, whether CysLT1 receptor antagonists such as montelukast can influence experimental nondissecting AAA remains unclear. Nondissecting AAAs were induced in C57BL/6J mice by transient aortic luminal infusion of porcine pancreatic elastase (PPE).
View Article and Find Full Text PDFCysteine Leukotriene Receptor Antagonist-Montelukast Effects on Diabetic Retinal Microvascular Endothelial Cells Curtail Autophagy.
Invest Ophthalmol Vis Sci
November 2024
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States.
Purpose: Diabetic macular edema (DME) is the primary cause of vision impairment in diabetic retinopathy (DR) patients. A previous study has shown the efficacy of montelukast, a cysteinyl leukotriene receptor (CysLTR)1 antagonist, in a diabetic mouse model. This study aims to understand the CysLTR1 signaling in retinal endothelial cells and the impact of montelukast.
View Article and Find Full Text PDFCYSLTR1 antagonism displays potent anti-tumor effects in uveal melanoma.
Exp Eye Res
November 2024
Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; The MUHC - McGill University Ocular Pathology & Translational Research Laboratory, Montreal, QC, Canada.
Article Synopsis
- * The study investigates the expression of the CYSLTR1 receptor in 31 human UM samples and shows that it is highly expressed in both primary and metastatic UM cells.
- * Blocking CYSLTR1 with the drug MK571 reduces UM cell growth and metabolic activity while increasing cell death, suggesting that targeting this receptor could be a promising treatment strategy for UM.
Cysteinyl Leukotrienes in Allergic Inflammation.
Annu Rev Pathol
January 2025
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
The cysteinyl leukotrienes (CysLTs), LTC, LTD, and LTE, are potent lipid mediators derived from arachidonic acid through the 5-lipoxygenase pathway. These mediators produce both inflammation and bronchoconstriction through three distinct G protein-coupled receptors (GPCRs)-CysLT, CysLT, and OXGR1 (also known as CysLT or GPR99). While CysLT-mediated functions in the effector phase of allergic inflammation and asthma have been established for some time, recent work has demonstrated novel roles for these mediators and their receptors in the induction and amplification of type 2 inflammation.
View Article and Find Full Text PDFThe role of signaling pathways mediated by the GPCRs CysLTR1/2 in melanocyte proliferation and senescence.
Sci Signal
September 2024
Laboratory of Chemical Biology and Signal Transduction, Rockefeller University, New York, NY 10065, USA.
Article Synopsis
- Melanoma caused by sun exposure differs from rarer types of melanocytic tumors, which have fewer mutations and allow researchers to explore specific signaling mechanisms.
- Uveal melanoma and blue nevi are examples of these rarer tumors, often linked to mutations in a particular signaling pathway involving G protein-coupled receptors.
- The study highlights how the same mutations can lead to cell growth in one tissue while hindering growth in another, illustrating how the tissue environment influences cell behavior and balance between growth and aging.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!